BridgeBio Pharma launches $250 million stock offering

Published on 3 Mar 2024 on Investing.com

BridgeBio Pharma, Inc. (NASDAQ: BBIO ), a biopharmaceutical company specializing in genetic diseases...

Read the rest of the article

Start tracking your investments with Statfolio

The approval came ahead of the targeted action date of Nov. 29. Per... Plunges on Study Failure...

Zacks · via Yahoo Finance 29 Nov 2024

BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults wit...

Zacks · via Yahoo Finance 26 Nov 2024

BridgeBio Pharma, Inc. (NASDAQ:BBIO) received U.S. Food and Drug Administration (FDA) approval fo...

Investing.com 25 Nov 2024

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks...

Investing.com 25 Nov 2024

(Bloomberg) -- BridgeBio Pharma Inc. jumped the most in 16 months after its drug got US regulator...

Bloomberg · via Yahoo Finance 25 Nov 2024

On Friday, the FDA approved BridgeBio Pharma, Inc.’s (NASDAQ:BBIO) Attruby (acoramidis), an...

Benzinga · via Yahoo Finance 25 Nov 2024

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, w...

Insider Monkey · via Yahoo Finance 21 Nov 2024

PALO ALTO, CA—Brian C. Stephenson, the Chief Financial Officer of BridgeBio Pharma, Inc....

Investing.com 20 Nov 2024

On Monday, BridgeBio Pharma, Inc. (NASDAQ:BBIO) presented initial outcomes from the ATTRibute-CM...

Benzinga · via Yahoo Finance 19 Nov 2024

One thing we could say about the analysts on BridgeBio Pharma, Inc. (NASDAQ:BBIO) - they aren't...

Simply Wall St. · via Yahoo Finance 18 Nov 2024